The Immune System
Had A Blueprint All Along.
We finally built from it.
CAR-T was invented before scientists fully understood how T cell receptors work. That single architectural gap created many of the limitations the field still faces today: toxic side effects, lack of persistence, cell exhaustion, relapse, and no path beyond heme malignancies.
The Problem
Cell therapies changed oncology.
They just can’t reach everyone who needs it.
Why First-Gen Cell Therapy Falls Short
Toxic
Side Effects
Uncontrolled immune activation limits who can safely receive treatment.
Preconditioning Needed
The need for the use of toxic chemotherapies and preconditioning regimens often exacerbate the patient state and add on to the toxic side effects.
Cell
Exhaustion & Relapse
Cells burn out.
Patients who achieved
remission lose it.
Solid Tumors Unreachable
The majority of cancer diagnoses remain beyond
first-gen therapy.
Manufacturing Bottleneck
Weeks of production.
Extraordinary cost.
Many patients
can't wait.
Cost
The price point for autologous CAR-Ts, TILs, and TCR technology is untenable and unsustainable for the majority of patients worldwide.
Disease
Restriction
Limited ability to translate to chronic diseases, such as autoimmune, inflammation, and CNS.
Our Solution
The blueprint was always there.
It took 30 years of science to act on it.
The Modulari-T SCIENCE
Two technologies. One system. Built from scratch.
MARC-Modular Actuation Receptor Complex
Next-generation immune receptor with separate targeting and signaling. On/off control. No exhaustion. Validated across five cell types.
MoVe-Modular Vector
First rationally designed delivery vehicle for in vivo cell and gene therapy. No liver toxicity. Precisely target immune or non-immune cells.